Interstitial Cystitis Market to Accelerate Substantially by 2032, Predicts DelveInsight | Leading Companies - Integrative Therapeutics, Lipella Pharmaceuticals, Allergan, Ironwood Pharmaceuticals, Vaneltix Pharma, Prevail Infoworks
13 déc. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Interstitial Cystitis Market to Accelerate Substantially by 2032, Predicts DelveInsight | Leading Companies - Integrative Therapeutics, Lipella...
Interstitial Cystitis Market to Receive Healthy Growth of USD 2,377.87 Million by 2029, Size, Share, Competitive Landscape, Regional Overview and Global Forecast
11 oct. 2022 10h17 HE
|
Data Bridge Market Research
BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- “Global Interstitial Cystitis Market” the new research report adds to Data Bridge Market Research’s reports database. This Research Report is spread across...
Solas BioVentures Co-Founder David Adair, M.D. Joins Mayfield Pharmaceuticals Board of Directors
23 oct. 2019 07h30 HE
|
Harrow Health, Inc.
BOSTON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced David Adair, M.D. will join the...
Mayfield Pharmaceuticals to Present at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019
08 oct. 2019 07h35 HE
|
Harrow Health, Inc.
BOSTON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its Chief Executive Officer, Melissa...
Harrow Health Announces Launch of Mayfield Pharmaceuticals
31 juil. 2019 07h30 HE
|
Harrow Health, Inc.
NASHVILLE, Tenn., July 31, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), today announced it has filed a Form 8-K with the Securities and Exchange Commission containing a corporate...
Aquinox to Present at LEERINK Partners 5th Annual Global Healthcare Conference
28 janv. 2016 09h15 HE
|
Neoleukin Therapeutics, Inc.
VANCOUVER, British Columbia, Jan. 28, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted...
Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA
11 janv. 2016 07h00 HE
|
Neoleukin Therapeutics, Inc.
VANCOUVER, British Columbia, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted...
Aquinox Pharmaceuticals Announces Closing of Initial Public Offering
12 mars 2014 12h58 HE
|
Neoleukin Therapeutics, Inc.
VANCOUVER, British Columbia, March 12, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP) announced today the closing of its initial public offering of 4,830,000 shares of its...
Aquinox Pharmaceuticals Prices Initial Public Offering
07 mars 2014 09h00 HE
|
Neoleukin Therapeutics, Inc.
VANCOUVER, British Columbia, March 7, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a...